GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...
GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.
The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in ...
Zydus Lifesciences' subsidiary partners with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will ...
A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...
External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback